LG Chem's CUE-102 cancer treatment to start Phase 1 trials

Home > Business > Industry

print dictionary print

LG Chem's CUE-102 cancer treatment to start Phase 1 trials

LG Chem researchers conduct tests at the company's lab. [LG CHEM]

LG Chem researchers conduct tests at the company's lab. [LG CHEM]

LG Chem's cancer immunotherapy candidate, CUE-102, won approval to start Phase 1 clinical trials from the U.S. Food and Drug Administration (FDA).
 
The trials will be conducted by Boston-based Cue Biopharma on patients with stomach cancer, pancreatic cancer, ovarian cancer and colorectal cancer to test its safety, tolerability and efficacy. CUE 102 is one of the three cancer immunotherapy candidates LG and Cue Biopharma jointly developed since 2018.
 
LG has the exclusive rights to develop and market the candidate in 11 Asian countries including Korea, China and Japan while Cue has it in all other countries.
 
If Cue succeeds in the Phase 1 trials, LG Chem will start Phase 2 trials in Asian countries.
 
The size of the global cancer immunotherapy market is expected to grow at an annual rate of 20 percent to reach $98.5 billion, according to data provided by research firm Evaluate Pharma.
 
LG Chem currently has 12 drug candidates in development, of which four are anticancer drugs.
 
CUE-101, its candidate for head and neck cancer, and GEN-001, a therapy for solid cancers, are undergoing Phase 1 clinical trials in the U.S. PDC lung, a candidate for non-small cell lung cancer, is in Phase 1 clinical trials in Europe. 
 

BY SARAH CHEA [chea.sarah@joongang.co.kr]
Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
s
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)